TScan is a fully integrated, next-generation TCR-T therapy company with a clinical-stage pipeline of next-gen heme and solid tumor TCR-T therapies.
Promising clinical data in heme TCR-T therapies with a focus on preventing relapse in patients undergoing allogeneic HCT.
Solid tumor program targeting tumor heterogeneity and HLA loss with a potential >$1B addressable market across US & EU.
Clinical Progress
Relapse prevention success in heme TCR-T therapy and promising advancements in solid tumor multiplex TCR-T therapy.
Manufacturing Updates
Engagement of a global CDMO to support late-stage manufacturing with multiple clinical catalysts expected by the end of 2025.
Financial Report
$218.0M funds secured as of June 30, 2025, sustaining operations into Q1 2027 with 129.8M total economic shares outstanding.
- TScan's success in preventing relapse in heme TCR-T therapy subjects showcases the potential of its innovative approach in the field of TCR-T therapies.
- The focus on solid tumor multiplex TCR-T therapy highlights TScan's commitment to overcoming tumor heterogeneity, addressing a significant market need.
With a strong clinical pipeline and sound financial position, TScan is positioned for further growth and development in the TCR-T therapy space, showing promising results in both heme and solid tumor programs.